ARTICLE | Clinical News
Ch806: Phase I data
March 12, 2007 7:00 AM UTC
In a dose-escalation, Australian Phase I trial in 8 cancer patients, ch806 showed tumor-specific targeting with no evidence of normal tissue uptake and no significant toxicity. Doses of up to 40 mg/m ...